Finance

Lists
LSI:FRA
CK Life Sciences Intl (Holdings) Inc
€0.058
0.00%
(0.00) 1D
Aug 19, 8:08:47 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LSI...
Mkt. cap
5.86B
Avg. vol.
0.00
Volume
0.00
52-wk high
€0.11
52-wk low
€0.06
No. of employees
2K
Mkt. cap
5.86B
Avg. vol.
0.00
Volume
0.00
52-wk high
€0.11
52-wk low
€0.06
No. of employees
2K
Profile
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Victor Li Tzar-kuoi, the eldest son of Li Ka-shing, the chairman of Cheung Kong Holdings. It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008. CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector. The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
About CK Life Sciences Intl (Holdings) Inc
CEOYing Choi Yu
Employees1.92K
Founded2000
Headquarters-
SectorBiotechnology
Websiteck-lifesciences.com
Previous reportsAll values in HKD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in HKD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.40B
1.40B
1.36B
1.36B
Cost of goods sold
1.01B
1.01B
975.61M
975.61M
Cost of revenue
1.01B
1.01B
975.61M
975.61M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
187.01M
187.01M
173.47M
173.47M
Operating expense
440.32M
440.32M
339.26M
339.26M
Total operating expenses
1.45B
1.45B
1.31B
1.31B
Operating income
-48.67M
-48.67M
43.01M
43.01M
Other non operating income
16.60M
16.60M
9.78M
9.78M
EBT including unusual items
58.42M
58.42M
-9.29M
-9.29M
EBT excluding unusual items
-87.93M
-87.93M
-9.29M
-9.29M
Income tax expense
77.23M
77.23M
15.02M
15.02M
Effective tax rate
132.19%
132.19%
-161.72%
-161.72%
Other operating expenses
231.88M
231.88M
143.42M
143.42M
Net income
-17.98M
-17.98M
-14.36M
-14.36M
Net profit margin
-1.28%
-1.28%
-1.06%
-1.06%
Earnings per share
-
-
-
-
Interest and investment income
5.36M
5.36M
3.26M
3.26M
Interest expense
-61.80M
-61.80M
-65.24M
-65.24M
Net interest expenses
-56.44M
-56.44M
-61.97M
-61.97M
Depreciation and amortization charges
20.80M
20.80M
21.66M
21.66M
EBITDA
11.09M
11.09M
85.98M
85.98M
Gain or loss from assets sale
-346.73M
-346.73M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps